Enanta Pharmaceuticals | ENTA - Efectivo Y Equivalentes





Efectivo Y Equivalentes Cambio Fecha
AbbVie USD 5.23B 400M 2025-12
Amgen USD 12.04B 2.91B 2026-03
Anika Therapeutics USD 41.02M 16.46M 2026-03
Arrowhead Research USD 201.64M 112.94M 2025-12
AstraZeneca USD 7.56B 1.85B 2026-03
BioCryst Pharmaceuticals USD 335.91M 251.83M 2025-12
Biogen USD 3.38B 374.2M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Gilead Sciences USD 7.56B 234M 2025-12
GlaxoSmithKline GBP 3.44B 292M 2026-03
Halozyme Therapeutics USD 133.82M 285.84M 2025-12
Heron Therapeutics USD 43.07M 26.55M 2025-09
Immunic USD 15.48M 19.65M 2025-12
Incyte USD 4.02B 435.22M 2026-03
Insmed USD 510.44M 175.68M 2025-12
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
J&J USD 21.69B 1.98B 2026-03
Karyopharm Therapeutics USD 60.54M 22.87M 2025-12
Ligand Pharmaceuticals USD 174.93M 489.59M 2025-12
Merck USD 5.33B 9.24B 2026-03
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Novartis USD 6.88B 4.56B 2026-03
Novavax USD 240.63M 27.39M 2025-12
Pfizer USD 1.7B 561M 2026-03
PTC Therapeutics USD 984.65M 312.03M 2025-12
Roche Holding CHF 7.55B 579M 2025-06
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03